E-Newsletter - December 2023
Scientific Annual Meetings



Alliance NCTN/NCORP/AFT at 2023 San antonio breast cancer symposium, american society of hematology Annual meetings



The San Antonio Breast Cancer Symposium (SABCS) is the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. Alliance presented five abstracts at this year's symposium held on December 5-9, 2023.


PO1-01-08: The Impact of Drug-Drug Interactions Between Palbociclib and Proton Pump Inhibitors on Clinical Outcomes of Patients with Hormone Receptor Positive, HER2-Negative, Early Breast Cancer: An Exploratory Analysis of the PALLAS Study
Elisa Agostinetto, MD, a medical research fellow at Brussels University Hospital, reported whether concomitant use of proton pump inhibitors (PPIs) could have affected clinical outcomes in patients treated with palbociclib in PALLAS. The PALLAS study randomized 5,796 patients to receive either 2 years of palbociclib with adjuvant endocrine therapy (ET) or ET alone and it is known that the addition of palbociclib did not improve invasive disease-free survival compared to adjuvant ET alone.

GS02-11: Fertility Preservation and Assisted Reproductive Technologies (ART) in Breast Cancer (BC) Patients Interrupting Endocrine Therapy (ET) to Attempt Pregnancy
Hatem A. Azim Jr, MD, PhD, of Monterrey Institute of Technology in Mexico, reported the use of fertility preservation and/or assisted reproductive technology (ART) appears safe for patients with hormone receptor (HR)-positive breast cancer who temporarily stop endocrine therapy to become pregnant.

PO4-25-04: MHC Class I and II Expression, Functional Tertiary Lymphoid Structure (TLS), and Outcomes in HER2-Positive (HER2+) Breast Cancer in the NCCTG N9831 (Alliance)
Saranya Chumsri, MD, a medical oncologist at Jacoby Center for Breast Health at Mayo Clinic Florida, reported a greater number of ectopic lymphoid aggregates (LA) was associated with improved outcomes in patients with early stage HER2+ breast cancer, particularly when treated with chemotherapy alone.

PO4-13-04: Added Value from Patient Advocates in a Translational Working Group: the COMET Study (AFT-25)
Deborah Collyar, of Patient Advocates in Research, reported that patient advocataes helped the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Translational Working Group set policy and oversaw biospecimen/image collection, and biobank use and sharing. Patients advocates also provided input to facilitate equitable, transparent research studies and technology development that could improve personalized decisions for surgery versus active monitoring in women with low-risk ductal carcinoma in situ.

PO2-01-06: Prognostic Value of Residual Disease Biology and Gene Expression Changes During the Neoadjuvant Treatment in HER2-positive Early-Breast Cancer
Aranzazu Fernandez-Martinez, MD, PhD, a medical oncologist at the University of North Carolina Chapel Hill, reported the findings could be relevant for implementing residual disease biomarkers in the clinic to stratify patients into different prognostic groups and tailor the post-operative treatment strategy.

PO3-02-05: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
Olga Kantor, MD, MS, a surgical oncologist at Brigham and Women's Hospital/Dana-Farber Cancer Institute, shared results on the racial and ethnic differences in toxicity, treatment duration, and disease outcomes in patients with early-stage HR+HER2- breast cancer treated with or without adjuvant palbociclib on the PALLAS trial.

PO1-01-13: Clinical Characterization, Prognostic and Predictive Values of HER2-low in Early Breast Cancer in the PALLAS trial (AFT-05)
Guilherme Nader-Marta, MD, a medical research fellow at Institut Jules Bordet, reported that in the large, prospective and international cohort, no differences were observed in clinical parameters, prognosis, or differential benefit from palbociclib (predictive value) between HER2-0 and HER2-low tumors.

PO3-18-11: Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in Patients with Residual HER2-positive Invasive Breast Cancer
Ciara C. O'Sullivan, MB, BCh, a medical oncologist at the Mayo Clinic in Rochester, MN, reported that Alliance A011801 (CompassHER2 RD) is an escalation trial for patients with high-risk HER2+ residue disease (RD) after neoadjuvant systemic therapy, evaluating the addition of the HER2 selective tyrosine kinase inhibitor (TKI) tucatinib to postneoadjuvant T-DM1.

GS03-07: Protocol-defined Biomarker Analysis in the PALLAS (AFT-05) Adjuvant Trial: Genomic Subtype Derived from RNA Sequencing of HR+/HER2- Early Breast Cancer
Daniel G. Stover, MD, a medical oncologist at the Ohio State University Comprehensive Cancer Center, shared that the translational analyses (TRANS-PALLAS) cohort represents one of the largest biorepositories of HR+/HER2- early breast cancer reflecting contemporary systemic management in the framework of a prospectively randomized global trial. Reported were the results for association of molecular subtype, proliferation score, and Risk of Recurrence (ROR) scores with invasive disease-free survival (IDFS) by treatment arm.

PO4-19-05: OptimICE-pCR: De-escalation of Therapy in Early-stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy (Alliance)
Sara M. Tolaney, MD, MPH, a medical oncologist at the Dana-Farber Cancer Institute, shared that the OptimICE-pCR trial utilizes response to preoperative therapy to tailor adjuvant therapy, and the goal is to determine whether patients who achieve pCR to pembrolizumab plus chemotherapy can achieve a similar recurrence-free survival with observation compared to adjuvant pembrolizumab monotherapy.

********************************************************************************


The American Society of Hematology (ASH) works to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training and advocacy in hematology. The society's scientific meetings facilitate the exchange of scientific information and clinical results related to the field of hematology. Alliance presented more than 10 abstracts at this year's symposium held on December 9-12, 2023 in San Diego, CA.


1575 BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Distinct Prognostically Poor Subgroup Enriched in Myelodysplasia-Related AML (Alliance)
Lead Author: Yazan Abu-Shihab, MD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis | Poster I

722 The Ancestry-related Landscape of Long Non-coding RNAs (lnCRNAs) in Acute Myeloid Leukemia (AML) and its Associated Impact on Patient Survival (Alliance)
Lead Author: Yazan Abu-Shihab, MD
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches

437 Ibrutinib Added to Standard Conditioning and As Consolidation Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Results from the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201
Lead Author: Charalambos Andreadis, MD
Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma | Oral

4126 Wilms’ Tumor 1 Functions as a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (Alliance)
Lead Author: Daelynn R. Buelow, PhD
Session: 602. Myeloid Oncogenesis: Basic | Poster III

4312 Ubtf- Tandem Duplications are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)
Lead Author: Emily Curran, MD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosisand Prognosis | Poster III (4312)

3340 Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)
Lead Author: Yvonne Efebera, MD
Program: Poster presentation
Session Name: 652. Multiple Myeloma: Clinical and Epidemiological | Poster II

380 Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort
Lead Author: Narendranath Epperla, MD, MS
Program: Oral
Session: 905. Outcomes Research – Lymphoid Malignancies

389 Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients (Pts) with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles (Alliance)
Lead Author: Alma Habib, MD
Session: 906.Outcomes Research - Myeloid Malignancies: Risk Factors and Health Disparities

4334 Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-mutated Acute Myeloid Leukemia from Blast Crisis Chronic Myelogenous Leukemia (Alliance)
Lead Author: Vanessa E. Kennedy, MD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis | Poster III

2954 Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients
Lead Author: Richard Marrero, PhD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis | Poster II

2934 Risk Stratification of Patients with RUNX1-mutated Acute Myeloid Leukemia (Alliance)
Lead Author: Christian Rausch, MD, PhD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis | Poster II

837 Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia (Alliance)
Lead Author: Andrew Stiff, MD, PhD
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

 

 

Read other articles in this month's e-newsletter: